Which antiplatelet agent is typically used for acute coronary syndromes?

Clopidogrel is commonly used for acute coronary syndromes due to its effectiveness in inhibiting platelet aggregation, which is crucial during events like unstable angina or myocardial infarction. It works by blocking the P2Y12 receptor on platelets, thereby preventing the activation and aggregation of platelets that can lead to clots. Clopidogrel is often administered in combination with aspirin to provide a dual antiplatelet therapy, which has been shown to significantly reduce the risk of subsequent cardiac events.

In the context of acute coronary syndromes, both clopidogrel and other antiplatelet agents like prasugrel are important, but clopidogrel is most widely recognized. Prasugrel is also used but may not be as universally applicable for all patients, particularly those at higher risk of bleeding. Warfarin, on the other hand, is an anticoagulant rather than an antiplatelet agent and is primarily used for conditions like atrial fibrillation and venous thromboembolism. Dipyridamole is mainly used in secondary prevention of thromboembolic events and is not typically used as a first-line treatment during acute coronary syndromes.